FDA approves Revolution Medicines' daraxonrasib for second-line pancreatic cancer

The U.S. Food and Drug Administration announced approval of Revolution Medicines' drug daraxonrasib for patients with pancreatic cancer who have already received prior therapy.

The approval marks the first FDA endorsement of a KRAS-targeted therapy for this indication, offering a new treatment option in a disease with limited options.

The decision follows the drug's evaluation for second-line use and is expected to expand therapeutic choices for clinicians and patients battling pancreatic cancer.